Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00674102 | An Open-label, Phase I Trial of Intravenous ASA404 Administered in Combination With Paclitaxel and Carboplatin in Japanese Patients With Non-Small Cell Lung Cancer (NSCLC) | PHASE1 | COMPLETED | 15 | — | — | Apr 1, 2008 | - | Dec 9, 2020 | 4 | Japan |
| Arm | Type | Description |
|---|---|---|
| ASA404 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| ASA404 | DRUG | - |
Inclusion criteria: 1. Histologically or cytologically confirmed non-small cell carcinoma of the lung. 2. Newly diagnosed Stage IIIb disease or Stage IV disease 3. No prior treatment for Stage IIIb/IV non-small cell carcinoma of the lung (Note: Prior neoadjuvant or adjuvant chemotherapy within 6 mo...